DEERFIELD, Ill. -
Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced an increase in the company's quarterly cash dividend to a rate of $0.29 per share of common stock. This represents an approximately 3.5% increase over the previous quarterly dividend rate of $0.28 per share. Baxter's Board of Directors declared the dividend payable on July 1, 2022, to stockholders of record as of June 3, 2022. The indicated annual dividend rate is now $1.16 per share of common stock.
"Baxter continues to advance its lifesaving Mission and deliver value for shareholders amid an unprecedented healthcare landscape," said José (Joe) E. Almeida, chairman, president and chief executive officer. "With our dedicated employees, diverse portfolio and disciplined approach to capital allocation, we are pleased to increase our dividend for the seventh straight year. We will continue to focus on advancing innovation, accelerating growth and realizing the potential of our Hillrom acquisition to benefit patients, caregivers, investors and the many other stakeholder communities that depend on us."
Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.
This release includes forward-looking statements concerning the company’s capital allocation, which currently includes the issuance of quarterly dividends. These forward-looking statements are based on assumptions about many factors and it is possible that Baxter's annual dividend payout rate may differ, possibly materially, from the anticipated annual indicative dividend described herein. For information about some of the risks and important factors that could affect Baxter's future results, financial condition and liquidity, see Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws.
Baxter and Hillrom are registered trademarks of Baxter International Inc. or its subsidiaries.